All In Biotech

Drug Trial Radar · NCT01696123

Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine

Last checked: Nov 19, 2026Latest source record: Sep 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

125

Actual

Start

Jan 2011

Primary completion

Jan 2012

Study completion Aug 2012

Sponsor

Lead sponsor
Shahid Beheshti University of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Current therapeutic approaches for the treatment of neurodegenerative diseases like Alzheimer disease (AD) offer limited and often transient symptomatic benefits to patients but do not mitigate the insidious loss of neuronal cells. In this trial the investigators will evaluate Efficacy and Tolerability of MLC601 as a neuroprotective in Patients with Mild to Moderate Alzheimer Disease who Were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.

Conditions

  • Alzheimer Disease

Interventions

  • MLC601Drug

    It was described

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. changes in the Mini-Mental State Examination (MMSE) relative to baseline measurementsTime frame: every 4 weeks up to 18 months
  2. changes in the cognitive subscale of the AD Assessment Scale (ADAS-cog) relative to baseline measurementsTime frame: every 4 weeks up to 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Loghman Hospital

    Tehran, Tehran Province, Iran

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.